Research graph
References from Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma. Local targets link to admitted publications; unresolved targets remain external evidence.
Primary central nervous system lymphoma
2017 · External reference
Trends in primary central nervous system lymphoma incidence and survival in the U.S
10.1111/bjh.14073 · 2016 · External reference
Epidemiology for primary brain tumors: a nationwide population-based study [published correction appears in J Neurooncol. 2017;131(3):547]
10.1007/s11060-016-2318-3 · 2017 · External reference
Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study
10.1007/s11060-020-03547-z · 2020 · External reference
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
10.1016/s0140-6736(09)61416-1 · 2009 · External reference
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (matrix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study group-32 (IELSG32) phase 2 trial
10.1016/s2352-3026(16)00036-3 · 2016 · External reference
Induction therapy with the matrix regimen in patients with newly diagnosed primary diffuse large b-cell lymphoma of the central nervous system – an international study of feasibility and efficacy in routine clinical practice
10.1111/bjh.16451 · 2020 · External reference
High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study
10.1182/bloodadvances.2020002064 · 2020 · External reference
Guidelines for the diagnosis and management of primary central nervous system diffuse large b-cell lymphoma
10.1111/bjh.15661 · 2019 · External reference
Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (alliance 50202)
10.1200/jco.2012.46.9957 · 2013 · External reference
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome
10.1200/jco.2013.50.4910 · 2013 · External reference
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study
10.1016/s1470-2045(18)30747-2 · 2019 · External reference
Radiotherapy (WBRT) or autologous stem-cell transplantation (ASCT) for primary CNS lymphoma in patients 60 years of age and younger: long-term results of the intergroup ANOCEF-Goelams Randomized Phase II PRECIS study
10.1182/blood-2021-146389 · 2021 · External reference
Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant
10.1001/jamaoncol.2021.1074 · 2021 · External reference
Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07
10.1200/jco.2003.03.036 · 2003 · External reference
Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation
10.1212/01.wnl.0000300671.37279.0e · 2008 · External reference
Intensive chemotherapy and immunotherapy, without brain irradiation, in newly diagnosed patients with primary CNS lymphoma: results of CALGB 50202
10.1182/blood.v116.21.763.763 · 2010 · External reference
10.1182/blood-2022-171733
10.1182/blood-2022-171733 · 2022 · External reference
Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant
10.1001/jamaoncol.2021.1074 · 2021 · External reference
The elderly left behind—changes in survival trends of primary central nervous system lymphoma over the past 4 decades
10.1093/neuonc/nox187 · 2018 · External reference
High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)
10.1038/leu.2016.334 · 2017 · External reference
Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly
10.1007/s11060-007-9397-0 · 2007 · External reference
Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group
10.3324/haematol.2014.108472 · 2015 · External reference
Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma
10.1111/bjh.15787 · 2019 · External reference
Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma
10.1158/2159-8290.cd-17-0613 · 2017 · External reference
Long-term outcomes of Rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS
10.2217/ijh-2017-0020 · 2017 · External reference
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma
10.1200/jco.2005.13.524 · 2005 · External reference
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS: 7-year results of the IELSG32 randomized trial
10.1038/s41375-022-01582-5 · 2022 · External reference
Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies
2024 · External reference
A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma—outcomes indicative for improved survival overtime
10.1002/hon.3198 · 2023 · External reference
A retrospective study of patient characteristics, treatment patterns and outcomes in patients with primary CNS lymphoma
10.1182/blood-2023-190843 · 2023 · External reference
Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model
10.1200/jco.2006.08.2941 · 2006 · External reference
Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience
10.1200/jco.2003.09.139 · 2003 · External reference
High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites
10.1038/bcj.2013.28 · 2013 · External reference
A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications
10.1016/j.ccell.2020.03.015 · 2020 · External reference
Genetics and pathogenesis of diffuse large B-cell lymphoma
10.1056/nejmoa1801445 · 2018 · External reference
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
10.1038/nm.3884 · 2015 · External reference
Phase 1b trial of an IBRUTINIB-based combination therapy in recurrent/refractory CNS lymphoma
10.1182/blood-2018-09-875732 · 2019 · External reference
Dose-adjusted teddi-R induces durable complete remissions in relapsed and refractory primary CNS lymphoma
10.1182/blood-2018-99-112184 · 2018 · External reference
